Fig 2.tif (4.8 MB)
Download fileBiodistribution of TTAC-0001 using Alexa Fluor® 647 reactive dye labeling.
figure
posted on 2018-01-25, 18:32 authored by Jinil Kim, Sang Hyun Choi, Su Jung Ham, Young Chul Cho, Seul-I Lee, Jeeheon Kang, Dong-Cheol Woo, Weon Sub Lee, Jin-San Yoo, Kyung Won Kim, Yoonseok Choi(A) Serial fluorescence images were acquired at baseline and at 1, 2, 4, and 8 h and 1, 2, 4, and 6 days after drug injection. (B) Plots of fluorescence accumulation at the tumor implantation site for each group show the serial changes over time. TTAC-2, TTAC-0001 2 mg/kg; TTAC-10, TTAC-0001 10 mg/kg.
History
Usage metrics
Read the peer-reviewed publication
Categories
Keywords
orthotopic xenograft tumor modelfuture treatment optionVEGFCD 31-positive cellsMatrigel plug angiogenesis assaysdrug mechanismBVZanti-Ki -67 antibodiesMDA-MBnovel anti-angiogenic agentmouse orthotopic breast cancer modelVEGFRgrowth factor receptorstumor growthbreast cancer cellsTTAC -2 groupsKi -67 indexbioluminescence imaginganti-tumor efficacyTTAC -10 groupmouse breast cancer orthotopic model Purpose Targeting
CC BY 4.0